Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The FAS-41BB switch receptor is an engineered chimeric receptor designed to redirect the pro-apoptotic signal induced by Fas ligand (FasL) in the tumor microenvironment into a pro-survival and costimulatory signal for T cells. It consists of the extracellular domain of Fas (CD95) fused to the intracellular signaling domain of 4-1BB (CD137). This receptor is primarily used in adoptive cell therapies, such as TCR-T and CAR-T cells, to enhance T cell persistence, proliferation, and anti-tumor activity within the suppressive tumor microenvironment by converting a death signal into an activating one.
Converts pro-apoptotic signals from FasL into pro-survival and costimulatory signals via 4-1BB, enhancing T cell activation and persistence in the tumor microenvironment.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FAS-41BB Switch Receptor (FAS-41BB).